J Infect Dis

• 

  Publication Venue For

  • Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study..  227:939-950. 2023
  • Wearable Sensor-Based Detection of Influenza in Presymptomatic and Asymptomatic Individuals..  227:864-872. 2023
  • Human Cytomegalovirus Infection Primes Fetal Natural Killer Cells for Fc-Mediated Antiviral Defense..  227:739-741. 2023
  • Imaging of Brain Structural and Functional Effects in People With Human Immunodeficiency Virus..  227:S16-S29. 2023
  • A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults. 2023
  • Inflammation and Metabolism of Influenza-Stimulated Peripheral Blood Mononuclear Cells From Adults With Obesity Following Bariatric Surgery..  227:92-102. 2022
  • Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children..  226:2069-2078. 2022
  • Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial..  226:1731-1742. 2022
  • Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy..  226:1809-1822. 2022
  • Characterization of Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus..  226:1667-1677. 2022
  • Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals..  226:1407-1411. 2022
  • Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia..  226:1109-1119. 2022
  • mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients..  226:797-807. 2022
  • Heterogeneity in Staphylococcus aureus Bacteraemia Clinical Trials Complicates Interpretation of Findings..  226:723-728. 2022
  • Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk..  226:246-257. 2022
  • Respiratory Syncytial Virus During the COVID-19 Pandemic Compared to Historic Levels: A Retrospective Cohort Study of a Health System..  226:S175-S183. 2022
  • Predictors of Plasmodium falciparum Infection in the First Trimester Among Nulliparous Women From Kenya, Zambia, and the Democratic Republic of the Congo..  225:2002-2010. 2022
  • Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021..  225:1694-1700. 2022
  • Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus..  225:1731-1740. 2022
  • Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat..  225:856-861. 2022
  • COVID-19 Vaccination Rates in a Global HIV Cohort..  225:603-607. 2022
  • Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model..  225:650-660. 2022
  • Modeling the Impacts of Clinical Influenza Testing on Influenza Vaccine Effectiveness Estimates..  224:2035-2042. 2021
  • Is SARS-CoV-2 Infection a Risk Factor for Early Pregnancy Loss? ACE2 and TMPRSS2 Coexpression and Persistent Replicative Infection in Primitive Trophoblast..  224:S660-S669. 2021
  • Placental Expression of ACE2 and TMPRSS2 in Maternal Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Are Placental Defenses Mediated by Fetal Sex?.  224:S647-S659. 2021
  • Reply to Day et al..  224:1627-1628. 2021
  • Cerebrospinal Fluid Pterins, Pterin-Dependent Neurotransmitters, and Mortality in Pediatric Cerebral Malaria..  224:1432-1441. 2021
  • Preclinical Testing of Vaccines and Therapeutics for Gonorrhea in Female Mouse Models of Lower and Upper Reproductive Tract Infection..  224:S152-S160. 2021
  • Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial..  223:352. 2021
  • Predicting Vibrio cholerae Infection and Disease Severity Using Metagenomics in a Prospective Cohort Study..  223:342-351. 2021
  • Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination..  222:S741-S744. 2020
  • Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?.  222:S794-S801. 2020
  • Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection..  222:2012-2020. 2020
  • Pathways to Leadership: Reflections of Recent Infectious Diseases Society of America (IDSA) Leaders During Conception and Launch of the Inclusion, Diversity, Access, and Equity Movement Within the IDSA..  222:S554-S559. 2020
  • Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium..  222:S175-S198. 2020
  • Interactions Between Antenatal Sulfadoxine-Pyrimethamine, Drug-Resistant Plasmodium falciparum Parasites, and Delivery Outcomes in Malawi..  222:661-669. 2020
  • An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus..  222:S41-S51. 2020
  • Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum..  222:S31-S40. 2020
  • Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial..  222:S20-S30. 2020
  • Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators..  222:S1-S7. 2020
  • Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial..  222:S63-S69. 2020
  • Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial..  222:S8-S19. 2020
  • Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE..  222:S52-S62. 2020
  • Extended ORF8 Gene Region Is Valuable in the Epidemiological Investigation of Severe Acute Respiratory Syndrome-Similar Coronavirus..  222:223-233. 2020
  • Surveillance for Spotted Fever Group Rickettsial Infections: Problems, Pitfalls, and Potential Solutions..  221:1238-1240. 2020
  • Mosquito Exposure and Malaria Morbidity: A Microlevel Analysis of Household Mosquito Populations and Malaria in a Population-Based Longitudinal Cohort in Western Kenya..  221:1176-1184. 2020
  • Choice of Study Populations for Vaccines..  221:S128-S134. 2020
  • Erratum to: Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single-Dose NVP: HIVNET 012..  221:855. 2020
  • Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants..  220:1802-1815. 2019
  • A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans..  220:862-872. 2019
  • Humoral Immune Correlates for Prevention of Postnatal Cytomegalovirus Acquisition..  220:772-780. 2019
  • Thrombocyte Inhibition Restores Protective Immunity to Mycobacterial Infection in Zebrafish..  220:524-534. 2019
  • Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period..  219:1755-1765. 2019
  • Obesity-Induced Changes in T-Cell Metabolism Are Associated With Impaired Memory T-Cell Response to Influenza and Are Not Reversed With Weight Loss..  219:1652-1661. 2019
  • Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine..  219:335-338. 2019
  • Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy..  218:1147-1154. 2018
  • Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease..  218:555-562. 2018
  • Human Gut Microbiota Predicts Susceptibility to Vibrio cholerae Infection..  218:645-653. 2018
  • Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial..  217:1280-1288. 2018
  • Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients..  216:1112-1121. 2017
  • Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi..  216:S474-S483. 2017
  • Minimal Impact by Antenatal Subpatent Plasmodium falciparum Infections on Delivery Outcomes in Malawian Women: A Cohort Study..  216:296-304. 2017
  • Gilding the Lily? Enhancing Antenatal Malaria Prevention in HIV-Infected Women..  216:4-6. 2017
  • Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial..  215:1255-1263. 2017
  • Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection..  215:S152-S159. 2017
  • Infection-Induced Vascular Permeability Aids Mycobacterial Growth..  215:813-817. 2017
  • Nitric Oxide-Dependent Endothelial Dysfunction and Reduced Arginine Bioavailability in Plasmodium vivax Malaria but No Greater Increase in Intravascular Hemolysis in Severe Disease..  214:1557-1564. 2016
  • Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women..  214:1050-1057. 2016
  • Determining the Incidence of Hepatitis C Virus Infection in Populations: An Important Tool for Epidemic Control..  214:339-340. 2016
  • History of AIDS in HIV-Infected Patients Is Associated With Higher In-Hospital Mortality Following Admission for Acute Myocardial Infarction and Stroke..  213:1955-1961. 2016
  • Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene..  213:1946-1954. 2016
  • Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in Humans..  213:1495-1504. 2016
  • Polymorphisms in HLA Class II Genes Are Associated With Susceptibility to Staphylococcus aureus Infection in a White Population..  213:816-823. 2016
  • Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide..  213:640-648. 2016
  • Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083..  213:541-550. 2016
  • Reply to Harrington et al..  213:497-498. 2016
  • Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection..  213:250-256. 2016
  • Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults..  213:14-22. 2016
  • λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies..  213:156-164. 2016
  • Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine..  212:525-530. 2015
  • Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes..  212:367-377. 2015
  • Moving toward prime time: host signatures for diagnosis of respiratory infections..  212:173-175. 2015
  • Symposium in Honor of Hilary Koprowski's Scientific Achievements..  212 Suppl 1:S1. 2015
  • The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women..  211:1997-2005. 2015
  • Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion..  211:947-955. 2015
  • Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study..  211:680-688. 2015
  • Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses..  211:508-517. 2015
  • Decreased endothelial nitric oxide bioavailability, impaired microvascular function, and increased tissue oxygen consumption in children with falciparum malaria..  210:1627-1632. 2014
  • Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults..  210:1270-1274. 2014
  • Dimethylarginines: endogenous inhibitors of nitric oxide synthesis in children with falciparum malaria..  210:913-922. 2014
  • Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot..  210:335-337. 2014
  • Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles..  210:99-110. 2014
  • Pooled deep sequencing of Plasmodium falciparum isolates: an efficient and scalable tool to quantify prevailing malaria drug-resistance genotypes..  208:1998-2006. 2013
  • A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis..  208:1914-1922. 2013
  • Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells..  208:1756-1767. 2013
  • Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine..  208:1386-1390. 2013
  • Safety of zoster vaccine in elderly adults following documented herpes zoster..  208:559-563. 2013
  • Virulence of endemic nonpigmented northern Australian Staphylococcus aureus clone (clonal complex 75, S. argenteus) is not augmented by staphyloxanthin..  208:520-527. 2013
  • Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients..  208:351-361. 2013
  • Influence of host genetics and environment on nasal carriage of staphylococcus aureus in danish middle-aged and elderly twins..  206:1178-1184. 2012
  • Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium..  206:1030-1040. 2012
  • Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection..  206:552-561. 2012
  • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials..  206:431-441. 2012
  • Clinical research and development of tuberculosis diagnostics: moving from silos to synergy..  205 Suppl 2:S159-S168. 2012
  • Toll-like receptor 1 polymorphisms increase susceptibility to candidemia..  205:934-943. 2012
  • Response of adipose tissue to early infection with Trypanosoma cruzi (Brazil strain)..  205:830-840. 2012
  • Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes..  205:376-383. 2012
  • Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients..  204:1663-1671. 2011
  • Quantification of the burden and consequences of pregnancy-associated malaria in the Democratic Republic of the Congo..  204:1762-1771. 2011
  • Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects..  204:1541-1549. 2011
  • Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza..  204:1358-1366. 2011
  • Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia..  204:1138-1145. 2011
  • Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women..  204:854-863. 2011
  • Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins..  204:704-713. 2011
  • Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet?.  204:329-331. 2011
  • Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine..  204:164-173. 2011
  • Whipple disease research accelerates..  204:4-5. 2011
  • Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy..  203:1629-1636. 2011
  • A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers..  203:1165-1173. 2011
  • Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009..  203:838-846. 2011
  • Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial..  203:773-779. 2011
  • Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles..  203:610-619. 2011
  • The humoral response to HIV-1: new insights, renewed focus..  202 Suppl 2:S315-S322. 2010
  • Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine..  202:595-605. 2010
  • Age-related susceptibility to severe malaria associated with galectin-2 in highland Papuans..  202:117-124. 2010
  • Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial..  201:1686-1696. 2010
  • Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy..  201:1035-1044. 2010
  • Domain 3 of hepatitis C virus core protein is sufficient for intracellular lipid accumulation..  200:1781-1788. 2009
  • Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria..  200:1522-1529. 2009
  • Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance..  200:1355-1366. 2009
  • Reply..  182:1005-1006. 2000
  • Reply..  181:812-813. 2000